JAZZ•benzinga•
Jazz Pharmaceuticals Reports Long-Term Phase 2 Data For Ziihera Showing 36.5-Month Median Overall Survival And Durable Responses In HER2-Positive Gastroesophageal Cancer, With Manageable Safety Profile; Results Presented At ASCO 2025 And Published In The
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga